Overexpression of HER2/neu, which is seen in approximately 30% of breast cancers, is associated with poor overall survival (Yu and Hung, 2000) and in particular with increased metastatic potential and resistance to chemotherapeutic agents. Here, ERBB2 is linked to breast cancer.